论文部分内容阅读
目的探讨依达拉奉联合血栓通对急性脑梗死患者血清超敏C反应蛋白(hs-CRP)和可溶性细胞间黏附分子-1(sICAM)的影响。方法 84例急性脑梗死患者随机分为两组,对照组40例,治疗组44例。对照组采用常规治疗,治疗组在常规治疗的基础上加用依达拉奉和血栓通,共治疗21d。治疗后评价疗效和测定血清hs-CRP和sICAM。结果对照组总有效率72.5%,治疗组总有效率为88.6%,两组差异有统计学意义(P<0.05)。两组在治疗后hs-CRP和sICAM均明显降低,但治疗组降低更明显(P<0.05)。结论依达拉奉联合血栓通可以减少急性脑梗死患者血清hs-CRP和sICAM的表达,从而治疗疾病。
Objective To investigate the effect of edaravone and xueshuantong on serum hs-CRP and sICAM in patients with acute cerebral infarction. Methods Eighty-four patients with acute cerebral infarction were randomly divided into two groups: control group (40 cases) and treatment group (44 cases). The control group was treated by conventional therapy. The treatment group was treated with edaravone and Xueshuantong for 21 days on the basis of routine treatment. After treatment, the curative effect was evaluated and serum hs-CRP and sICAM were measured. Results The total effective rate of the control group was 72.5%, and the total effective rate of the treatment group was 88.6%. There was significant difference between the two groups (P <0.05). After treatment, both hs-CRP and sICAM were significantly lower, but the treatment group decreased more significantly (P <0.05). Conclusion Edaravone combined with Xueshuantong can reduce the expression of serum hs-CRP and sICAM in patients with acute cerebral infarction and thus treat the disease.